The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).
 
Omran Saifi
No Relationships to Disclose
 
William Breen
No Relationships to Disclose
 
Scott Lester
No Relationships to Disclose
 
William G. Rule
No Relationships to Disclose
 
Brad J. Stish
No Relationships to Disclose
 
Allison Claire Rosenthal
No Relationships to Disclose
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Nabila Nora Bennani
Consulting or Advisory Role - Affimed Therapeutics (Inst); Daiichi Sankyo (Inst); Kymera (Inst); Kyowa Kirin International (Inst); Purdue Pharma (Inst); Secura Bio (Inst); Verastem (Inst); Vividion Therapeutics (Inst)
Research Funding - Kite, a Gilead company (Inst)
 
Jonas Paludo
Research Funding - Biofourmis (Inst); Karyopharm Therapeutics (Inst)
 
Arushi Khurana
No Relationships to Disclose
 
Jose Caetano Villasboas
Consulting or Advisory Role - Curio Science (Inst); Kite/Gilead (Inst); Regeneron (Inst); TG Therapeutics (Inst)
Research Funding - Aptose Biosciences (Inst); Enterome (Inst); Epizyme (Inst); Regeneron (Inst)
 
Patrick B. Johnston
No Relationships to Disclose
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Madiha Iqbal
No Relationships to Disclose
 
Muhamad Alhaj Moustafa
Consulting or Advisory Role - Acrotech Biopharma (Inst); CSL Behring
 
Hemant S. Murthy
Research Funding - crispr therapeutics (Inst)
 
Mohamed Kharfan-Dabaja
No Relationships to Disclose
 
Bradford Hoppe
Consulting or Advisory Role - Merck (Inst)
 
Jennifer Peterson
No Relationships to Disclose